A61K 9/2054
Cellulose
Official title: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
A61K9/2054 (Cellulose) appears on 4,435 US grants and 9,222 published applications in this corpus.
Search patents in A61K- Granted patents
- 4,435
- Published applications
- 9,222
- Assignees
- 2,501
- Inventors
- 13,431
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 4 | 0 |
| 1977 | 2 | 0 |
| 1978 | 4 | 0 |
| 1979 | 1 | 0 |
| 1980 | 4 | 0 |
| 1981 | 3 | 0 |
| 1982 | 3 | 0 |
| 1983 | 3 | 0 |
| 1984 | 3 | 0 |
| 1985 | 11 | 0 |
| 1986 | 6 | 0 |
| 1987 | 9 | 0 |
| 1988 | 13 | 0 |
| 1989 | 27 | 0 |
| 1990 | 15 | 0 |
| 1991 | 21 | 0 |
| 1992 | 13 | 0 |
| 1993 | 12 | 0 |
| 1994 | 9 | 0 |
| 1995 | 20 | 0 |
| 1996 | 26 | 0 |
| 1997 | 29 | 0 |
| 1998 | 34 | 0 |
| 1999 | 53 | 0 |
| 2000 | 65 | 0 |
| 2001 | 93 | 41 |
| 2002 | 67 | 115 |
| 2003 | 92 | 259 |
| 2004 | 64 | 223 |
| 2005 | 57 | 256 |
| 2006 | 50 | 234 |
| 2007 | 37 | 250 |
| 2008 | 37 | 295 |
| 2009 | 30 | 270 |
| 2010 | 83 | 316 |
| 2011 | 94 | 316 |
| 2012 | 111 | 311 |
| 2013 | 178 | 408 |
| 2014 | 236 | 455 |
| 2015 | 242 | 477 |
| 2016 | 260 | 492 |
| 2017 | 296 | 481 |
| 2018 | 226 | 420 |
| 2019 | 228 | 409 |
| 2020 | 238 | 449 |
| 2021 | 261 | 458 |
| 2022 | 229 | 484 |
| 2023 | 208 | 466 |
| 2024 | 250 | 464 |
| 2025 | 224 | 478 |
| 2026 | 154 | 395 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Dosage forms for TYK2 inhibitors6 Oct 2026US 12,751,948 B2Bristol-Myers Squibb Company
- Formulation for oral administration, comprising triazine derivative6 Oct 2026US 12,751,955 B2Shionogi & Co., Ltd.
- Combination drug for the control and management of type 2 diabetes mellitus6 Oct 2026US 12,751,958 B2Laboratorios Silanes S.A. de C.V.
- Oral formulations and uses thereof29 Sep 2026US 12,746,229 B2Inventisbio Co., Ltd.
- Anticancer compositions29 Sep 2026US 12,746,230 B2Aragon Pharmaceuticals, Inc.
- Pharmaceutical oral dosage form of q2038 Oct 2026US 2026/0306411 A1Qurient Co., Ltd.
- Triptolide formulations8 Oct 2026US 2026/0306412 A1Minneamrita Therapeutics LLC
- Compounds and combinations thereof for treating neurological and psychiatric conditions8 Oct 2026US 2026/0306426 A1Antecip Bioventures II LLC
- Method and pharmaceutical composition for treating a sleep disorder8 Oct 2026US 2026/0306442 A1Overseas Pharmaceuticals, Ltd.
- Formulations containing tryptamine derivatives and uses thereof8 Oct 2026US 2026/0306453 A1Psilera Inc.
Most cited
By later US patents
- Controlled release oxycodone compositions466US 5,508,042 AEuro-Celtigue, S.A. · 1996
- Orally administrable opioid formulations having extended duration of effect437US 5,968,551 APurdue Pharma L. P. · 1999
- Controlled release oxycodone compositions436US 5,266,331 AEuroceltique, S.A. · 1993
- Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose432US 4,389,393 AForest Laboratories, Inc. · 1983
- Controlled release oxycodone compositions411US 5,549,912 AEuro-Celtique S. A. · 1996